SCHEDULE 13G/A: W. Thorpe McKenzie Discloses 9.71% Passive Stake in XBIOTECH, INC.

W. Thorpe McKenzie has filed an amended Schedule 13G, reporting a 9.71% beneficial ownership stake in XBIOTECH, INC. as of December 31, 2024.

Summary

• W. Thorpe McKenzie beneficially owns 2,987,509 common shares of XBIOTECH, INC.
• This ownership represents 9.71% of the company's outstanding common shares, calculated based on 30,487,731 shares outstanding as of December 31, 2024.
• The reported figures include common stock underlying stock options held by Mr. McKenzie that are immediately exercisable within 60 days of December 31, 2024.
• Mr. McKenzie holds sole voting and dispositive power over 2,881,221 shares.
• Shared voting and dispositive power applies to 106,288 shares, which include 66,748 shares held by the McKenzie Foundation, 31,864 shares held by Mr. McKenzie's spouse, and 7,676 shares held in a Trust for Mr. McKenzie's stepchildren.
• Mr. McKenzie disclaims beneficial ownership of the shares held by his spouse, the McKenzie Foundation, and the Trust for his stepchildren, except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing indicates a significant, stable, passive investment by an individual, which can be seen as a vote of confidence, but it contains no new operational or financial news.

Positives

• A significant individual investor, W. Thorpe McKenzie, maintains a substantial stake (9.71%) in XBIOTECH, INC., indicating continued confidence in the company.
• The filing is a Schedule 13G, which typically signifies a passive investment intent rather than an activist stance, potentially providing stability for company management.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard disclosure of a significant passive ownership stake in a biotechnology company. Such filings are common and provide transparency regarding major shareholders, which can influence market perception of stability and investor confidence within the biotech sector.

Comparison to Industry Standards

• This document is a routine ownership disclosure and does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant individual shareholder's stake, potentially influencing investor confidence.
• Company Management: Confirms a large, passive shareholder, which typically implies less immediate pressure for strategic changes compared to an activist investor.

Key Dates

Keywords

XBIOTECH, W. Thorpe McKenzie, Schedule 13G, Beneficial Ownership, Common Shares, SEC Filing, Biotechnology, Passive Investment